Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06393738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 19 to 21v18
  2. Enrollment increased: 255 → 329 participants
    • Study sites: 17 to 19
    • Eligibility criteria expanded, about 51 words
    v17
  3. Enrollment target: 112 to 255v16 Show 7 more changesShow less
    • Primary and study completion dates: Dec 2025 to Mar 2028
    • Primary endpoints revised (4)
    • Interventions: ARV-393 (Drug) to ARV-393 (Drug), Glofitamab (Drug)
    • Eligibility criteria expanded, about 173 words
    • Secondary endpoints: 9 to 10
    • Study description expanded, about 64 words
    • Study arms: 1 to 4
  4. Study sites: 16 to 17v15
  5. Study sites: 15 to 16v14
Show 12 earlier versionsHide 12 earlier versions
  1. Site details revised at 1 of 15 sitesv13
  2. Site details revised at 3 of 15 sitesv12
  3. Study sites: 14 to 15v11
  4. Site details revised at 1 of 14 sitesv10
  5. Site details revised at 1 of 14 sitesv9
  6. Site details revised at 3 of 14 sitesv8
  7. Site details revised at 1 of 14 sitesv7
  8. Study sites: 12 to 14v6
  9. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Aug 12, 2024 to Sep 5, 2024
    • Site details revised at 12 of 12 sites
    v5
  10. Re-verified, no change to tracked fieldsv4
  11. Study sites: 1 to 12v3
  12. Start date: Apr 30, 2024 to Aug 12, 2024
    • Trial status: Recruiting to Not Yet Recruiting
    • Study sites: 8 to 1
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Trial Details
NCT Number NCT06393738
Lead Sponsor Arvinas Inc.
Conditions
(from sponsor)		 Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Related terms Immunoblastic Lymphadenopathy, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Recurrence
Enrollment 329 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov